<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873286</url>
  </required_header>
  <id_info>
    <org_study_id>RSV-MVA-002</org_study_id>
    <nct_id>NCT02873286</nct_id>
  </id_info>
  <brief_title>RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults</brief_title>
  <official_title>A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 400 subjects will be recruited into five treatment subject groups à 80&#xD;
      subjects.Subject will receive two administrations 4 weeks apart which will consist of&#xD;
      MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS).&#xD;
&#xD;
      86 subjects from 2 treatment groups (43 per treatment group) are supposed to receive one&#xD;
      (booster) dose of MVA-BN-RSV vaccine approximately one year after their first vaccination. In&#xD;
      this booster substudy, eligible subjects will receive the same dose they received during the&#xD;
      main trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRNT (Subtype A) GMT</measure>
    <time_frame>Week 6 (Main Study) i.e., 2 weeks following the second vaccination</time_frame>
    <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRNT (Subtype A) GMT</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by PRNT (Subtype A)</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT (Subtype B) GMT</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by PRNT (Subtype B)</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA (IgG) GMT</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '31.5' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by IgG ELISA</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Response rate based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (63) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA (IgA) GMT</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '50' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by IgA ELISA</measure>
    <time_frame>within 108 weeks</time_frame>
    <description>Response rate based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (100) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA (Mucosal IgA) GMT</measure>
    <time_frame>within 82 weeks</time_frame>
    <description>Geometric Mean Titers (GMTs) based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '1' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by Mucosal IgA ELISA</measure>
    <time_frame>within 82 weeks</time_frame>
    <description>Response rate based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (2) for initially negative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IFN-g, Peptide Pool: F) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IFN-g, Peptide Pool: G(A)) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IFN-g, Peptide Pool: G(B)) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IFN-g, Peptide Pool: M2) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IFN-g, Peptide Pool: N) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IL-4, Peptide Pool: F) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IL-4, Peptide Pool: G(A)) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IL-4, Peptide Pool: G(B)) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IL-4, Peptide Pool: M2) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT (IL-4, Peptide Pool: N) GMSFU</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: F)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(A))</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(B))</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: M2)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: N)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: F)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(A))</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(B))</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: M2)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: N)</measure>
    <time_frame>within 58 weeks</time_frame>
    <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory B Cells (IgG) GMSFU</measure>
    <time_frame>within 82 weeks</time_frame>
    <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Immunoglobulin G (IgG)-producing memory B cells. Negative results (i.e. results below 0.01) are included with a value of '0.005'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
    <description>Number of participants reporting Serious Adverse Events per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Serious Adverse Events</measure>
    <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
    <description>Number of participants reporting Serious Adverse Events possibly, probably or definitely related to the trial vaccine per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 Serious Adverse Events</measure>
    <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
    <description>Number of participants reporting Serious Adverse Events with intensity ≥ Grade 3 per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Grade ≥ 3 Adverse Events</measure>
    <time_frame>within 29 days after vaccination</time_frame>
    <description>Number of participants reporting Adverse Events possibly, probably or definitely related to the trial vaccine with intensity ≥ Grade 3 per period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Pooled solicited (general only) and unsolicited AEs. Percentages based on number of subjects still in the study at the start of the respective period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Incidence of injection site reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Incidence of injection site reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited General Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Incidence of systemic reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 Solicited General Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Incidence of systemic reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Solicited General Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Incidence of systemic reactions (solicited via diary cards) possibly, probably or definitely related to the trial vaccine after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 29 days after vaccination</time_frame>
    <description>Incidence of unsolicited non-serious adverse events by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 29 days after vaccination</time_frame>
    <description>Incidence of unsolicited non-serious adverse events possibly, probably or definitely related to the trial vaccine by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 29 days after vaccination</time_frame>
    <description>Incidence of unsolicited non-serious adverse events with intensity ≥ Grade 3 by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Group 1 - Single Low Dose / Booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Two Low Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Single High Dose / Booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Two High Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-RSV</intervention_name>
    <description>MVA-mBN294B</description>
    <arm_group_label>Group 1 - Single Low Dose / Booster</arm_group_label>
    <arm_group_label>Group 2 - Two Low Doses</arm_group_label>
    <arm_group_label>Group 3 - Single High Dose / Booster</arm_group_label>
    <arm_group_label>Group 4 - Two High Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tris Buffered Saline, sterile</description>
    <arm_group_label>Group 1 - Single Low Dose / Booster</arm_group_label>
    <arm_group_label>Group 3 - Single High Dose / Booster</arm_group_label>
    <arm_group_label>Group 5 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Main study):&#xD;
&#xD;
          1. Male and female subjects, ≥ 55 years of age.&#xD;
&#xD;
          2. Prior to performance of any trial specific procedures, the subject has read, signed&#xD;
             and dated an informed consent form, having been advised of the risks and benefits of&#xD;
             the trial in a language understood by the subject, and has signed the Health Insurance&#xD;
             Portability and Accountability Act (HIPAA) authorization form.&#xD;
&#xD;
          3. Subjects without symptomatic cardiopulmonary and/or metabolic disease. Note that&#xD;
             subjects who have any active symptoms related to cardiac and/or pulmonary and/or&#xD;
             metabolic disease (including e.g. uncontrolled asthma, angina pectoris, hyperglycaemia&#xD;
             or other episodic symptoms), or who receive ongoing therapy to control current, active&#xD;
             symptoms, are not eligible. Subjects on stable treatment (no change in ≥ 1 month) for&#xD;
             previous and controlled symptoms or conditions are eligible. The following are&#xD;
             examples of subjects who may bear cardiopulmonary or metabolic diagnoses but who would&#xD;
             remain eligible:&#xD;
&#xD;
               -  Subjects on stable (no change in ≥ 1 month) therapy for findings (e.g.&#xD;
                  hypertension, hyperlipidemia) which are not associated with current symptoms or&#xD;
                  disability.&#xD;
&#xD;
               -  Subjects with type II diabetes mellitus are considered eligible as long as they&#xD;
                  are stable on oral antidiabetics and have either a documented glycated hemoglobin&#xD;
                  (HbA1c) of ≤ 8 % within three months prior to trial participation or confirmation&#xD;
                  of controlled blood glucose level must be obtained at the SCR (screening) visit&#xD;
                  by a lab test.&#xD;
&#xD;
               -  Subjects who receive short term treatment for temporary conditions.&#xD;
&#xD;
               -  Other clinically insignificant findings not deemed to be associated with&#xD;
                  increased risk for respiratory viral infections as determined by the&#xD;
                  investigator.&#xD;
&#xD;
          4. Able to comply with trial requirements; including access to transportation for trial&#xD;
             visits.&#xD;
&#xD;
          5. Body mass index (BMI) ≥ 18.5 and ≤ 39.9&#xD;
&#xD;
             BMI formula for pounds and inches:&#xD;
&#xD;
             BMI = (bodyweight in pounds) * 703 (bodyheight in inches)2&#xD;
&#xD;
          6. Women of childbearing potential (WOCBP) must have used an acceptable method of&#xD;
             contraception for at least 30 days prior to the first vaccination, must agree to use&#xD;
             an acceptable method of contraception (as defined in Section 8.2.11) during the trial,&#xD;
             and must avoid becoming pregnant for at least 28 days after the last vaccination.&#xD;
             WOCBP must have a negative serum pregnancy test at screening and a negative urine&#xD;
             pregnancy test prior to each vaccination&#xD;
&#xD;
          7. Not clinically significant laboratory values as defined in the protocol, excluding any&#xD;
             Grade ≥ 3 toxicity.&#xD;
&#xD;
          8. Negative human immunodeficiency virus antibody test (anti-HIV), negative hepatitis B&#xD;
             surface antigen (HBsAG) and negative antibody test to hepatitis C virus.&#xD;
&#xD;
          9. Electrocardiogram (ECG) without clinically significant acute findings (e.g. findings&#xD;
             suggestive of current ischemia, ventricular arrhythmias, congestive heart failure and&#xD;
             ventricular hypertrophy).&#xD;
&#xD;
        Exclusion Criteria (Main Study):&#xD;
&#xD;
          1. Pregnant or breast-feeding women.&#xD;
&#xD;
          2. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy.&#xD;
&#xD;
          3. History or current clinical manifestation of any serious medical condition, which in&#xD;
             the opinion of the investigator would compromise the safety of the subject or would&#xD;
             limit the subject's ability to complete the trial.&#xD;
&#xD;
               -  History of cerebrovascular disorders, including stroke. Patients with history of&#xD;
                  transient ischaemic attack (TIA) ≥ 1 year prior to trial participation remain&#xD;
                  eligible.&#xD;
&#xD;
               -  History of myocardial infarction within ≤ 1 year prior to trial participation,&#xD;
                  current clinical manifestation of angina pectoris, current clinical manifestation&#xD;
                  of congestive heart failure ≥ New York Heart Association (NYHA) Grade II,&#xD;
                  uncontrolled high blood pressure defined as systolic blood pressure ≥ 150 mmHg&#xD;
                  and/or diastolic ≥ 100 mmHg within the last 2 months.&#xD;
&#xD;
          4. History of or active autoimmune disease. Persons with vitiligo or thyroid disease&#xD;
             taking thyroid replacement are not excluded. Persons with rheumatoid arthritis not&#xD;
             requiring immunomodulatory and/or immunosuppressant treatment are not excluded.&#xD;
&#xD;
          5. Known or suspected impairment of immunologic functions including, but not limited to&#xD;
             chronic inflammatory bowel disorders, diabetes mellitus type I.&#xD;
&#xD;
          6. History of malignancy other than squamous cell or basal cell skin cancer, unless there&#xD;
             has been surgical excision at least 6 months ago that is considered to have achieved&#xD;
             cure. Subjects with history of skin cancer should not be vaccinated at the previous&#xD;
             tumor site.&#xD;
&#xD;
          7. Clinically significant mental disorder, not adequately controlled by medical&#xD;
             treatment.&#xD;
&#xD;
          8. Active or recent (within the time period of six months before trial participation)&#xD;
             history of chronic alcohol abuse and/or intravenous and/or nasal drug abuse.&#xD;
&#xD;
          9. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine, e.g. tris(hydroxymethyl)-amino methane, chicken embryo fibroblast&#xD;
             proteins, gentamycin.&#xD;
&#xD;
         10. Known allergy to eggs or aminoglycosides.&#xD;
&#xD;
         11. History of anaphylaxis or severe allergic reaction to any vaccine.&#xD;
&#xD;
         12. Having received any vaccinations or planned vaccinations with a live vaccine within 30&#xD;
             days prior to or after trial vaccination.&#xD;
&#xD;
         13. Having received any vaccinations or planned vaccinations with an inactivated vaccine&#xD;
             within 14 days prior to or after trial vaccination.&#xD;
&#xD;
         14. Chronic systemic administration (defined as more than 14 days) of &gt; 5 mg prednisone&#xD;
             (or equivalent)/day or any other immune-modifying drugs during a period starting from&#xD;
             three months prior to first administration of the trial vaccination and ending at the&#xD;
             last visit of the active trial phase. The use of topical, inhaled, ophthalmic and&#xD;
             nasal glucocorticoids is permitted.&#xD;
&#xD;
         15. Administration or planned administration of immunoglobulins and/or any blood products&#xD;
             during a period starting from three months prior to first administration of the trial&#xD;
             vaccination and ending at the last visit of the active trial phase.&#xD;
&#xD;
         16. Use of any investigational or non-registered drug or vaccine other than the trial&#xD;
             vaccine within 30 days preceding the first trial vaccination, or planned&#xD;
             administration of such a drug between participation in the trial and until 4 weeks&#xD;
             after last trial vaccination.&#xD;
&#xD;
         17. Previous or planned vaccination with a RSV vaccine/vaccine candidate.&#xD;
&#xD;
         18. Clinical trial personnel working on the current trial.&#xD;
&#xD;
        Inclusion Criteria (Substudy):&#xD;
&#xD;
          1. Prior to performance of any booster substudy specific procedures, the subject has&#xD;
             read, signed and dated an informed consent form, having been advised of the risks and&#xD;
             benefits of the trial in a language understood by the subject.&#xD;
&#xD;
          2. Subject has completed all vaccinations of the main trial according to protocol.&#xD;
&#xD;
        Exclusion Criteria (Substudy):&#xD;
&#xD;
          1. Any condition that, in the opinion of the investigator, makes it unsafe for the&#xD;
             subject to receive a further vaccination.&#xD;
&#xD;
          2. Pregnancy.&#xD;
&#xD;
          3. An anaphylactic reaction following the administration of any vaccine(s).&#xD;
&#xD;
          4. Clinical need for concomitant or ancillary therapy not permitted in the trial as&#xD;
             outlined in Protocol Section 8.2.2.&#xD;
&#xD;
          5. Having received any vaccinations or planned vaccinations with a live vaccine within 30&#xD;
             days prior to or after booster vaccination.&#xD;
&#xD;
          6. Having received any vaccinations or planned vaccinations with an inactivated vaccine&#xD;
             within 14 days prior to or after booster vaccination.&#xD;
&#xD;
          7. Chronic systemic administration (defined as more than 14 days) of &gt; 5 mg prednisone&#xD;
             (or equivalent)/day or any other immune-modifying drugs during a period starting from&#xD;
             3 months prior to administration of the booster vaccine and ending at the last visit&#xD;
             of the booster active trial phase. The use of topical, inhaled, ophthalmic and nasal&#xD;
             glucocorticoids is permitted.&#xD;
&#xD;
          8. Administration or planned administration of immunoglobulins and/or any blood products&#xD;
             during a period starting from 3 months prior to administration of the booster vaccine&#xD;
             and ending at the last visit of the booster active trial phase.&#xD;
&#xD;
          9. Use of any investigational or non-registered drug or vaccine other than the trial&#xD;
             vaccine within 30 days preceding the booster vaccination, or planned administration of&#xD;
             such a drug during participation in the booster substudy and until 4 weeks after&#xD;
             booster vaccination.&#xD;
&#xD;
         10. Subject's request to discontinue&#xD;
&#xD;
         11. Subject's refusal to receive booster vaccination.&#xD;
&#xD;
         12. Subject unwilling or unable to comply with trial requirements. Any reason that, in the&#xD;
             opinion of the investigator contradicts administration of the booster vaccination or&#xD;
             otherwise requires early discontinuation of a subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Lawrence, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paradigm Research</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research Associates</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2020</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV Vaccines</keyword>
  <keyword>Respiratory Syncytial Virus Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02873286/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02873286/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Single Low Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Two Low Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - Single High Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="P4">
          <title>Group 4 - Two High Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="P5">
          <title>Group 5 - Placebo</title>
          <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="89"/>
                <participants group_id="P5" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Booster Substudy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Single Low Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Two Low Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - Single High Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="B4">
          <title>Group 4 - Two High Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="B5">
          <title>Group 5 - Placebo</title>
          <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="90"/>
            <count group_id="B5" value="83"/>
            <count group_id="B6" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="8.09"/>
                    <measurement group_id="B2" value="64.8" spread="7.78"/>
                    <measurement group_id="B3" value="65.3" spread="7.18"/>
                    <measurement group_id="B4" value="65.0" spread="7.93"/>
                    <measurement group_id="B5" value="65.6" spread="7.20"/>
                    <measurement group_id="B6" value="65.2" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>55 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="82"/>
                    <measurement group_id="B6" value="404"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="83"/>
                    <measurement group_id="B6" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PRNT (Subtype A) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
        <time_frame>Week 6 (Main Study) i.e., 2 weeks following the second vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Calculations based on participants with data available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT (Subtype A) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Calculations based on participants with data available for this outcome.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.5" lower_limit="251.7" upper_limit="358.6"/>
                    <measurement group_id="O2" value="278.9" lower_limit="239.2" upper_limit="325.2"/>
                    <measurement group_id="O3" value="311.9" lower_limit="261.7" upper_limit="371.7"/>
                    <measurement group_id="O4" value="373.3" lower_limit="320.9" upper_limit="434.2"/>
                    <measurement group_id="O5" value="229.3" lower_limit="195.2" upper_limit="269.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT (Subtype A) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT (Subtype A) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.4" lower_limit="214.2" upper_limit="307.0"/>
                    <measurement group_id="O2" value="208.0" lower_limit="180.0" upper_limit="240.3"/>
                    <measurement group_id="O3" value="234.9" lower_limit="200.4" upper_limit="275.3"/>
                    <measurement group_id="O4" value="276.4" lower_limit="235.9" upper_limit="323.9"/>
                    <measurement group_id="O5" value="251.7" lower_limit="213.7" upper_limit="296.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.7" lower_limit="266.3" upper_limit="376.6"/>
                    <measurement group_id="O2" value="259.8" lower_limit="222.5" upper_limit="303.4"/>
                    <measurement group_id="O3" value="356.9" lower_limit="298.8" upper_limit="426.4"/>
                    <measurement group_id="O4" value="398.8" lower_limit="340.8" upper_limit="466.6"/>
                    <measurement group_id="O5" value="235.0" lower_limit="202.1" upper_limit="273.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.5" lower_limit="259.0" upper_limit="365.2"/>
                    <measurement group_id="O2" value="258.2" lower_limit="218.6" upper_limit="304.9"/>
                    <measurement group_id="O3" value="342.5" lower_limit="287.5" upper_limit="408.1"/>
                    <measurement group_id="O4" value="347.7" lower_limit="296.9" upper_limit="407.2"/>
                    <measurement group_id="O5" value="252.7" lower_limit="214.2" upper_limit="298.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.5" lower_limit="251.7" upper_limit="358.6"/>
                    <measurement group_id="O2" value="278.9" lower_limit="239.2" upper_limit="325.2"/>
                    <measurement group_id="O3" value="311.9" lower_limit="261.7" upper_limit="371.7"/>
                    <measurement group_id="O4" value="373.3" lower_limit="320.9" upper_limit="434.2"/>
                    <measurement group_id="O5" value="229.3" lower_limit="195.2" upper_limit="269.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.0" lower_limit="246.6" upper_limit="345.7"/>
                    <measurement group_id="O2" value="263.9" lower_limit="226.9" upper_limit="306.9"/>
                    <measurement group_id="O3" value="304.0" lower_limit="251.8" upper_limit="367.1"/>
                    <measurement group_id="O4" value="370.9" lower_limit="316.3" upper_limit="434.9"/>
                    <measurement group_id="O5" value="231.5" lower_limit="197.4" upper_limit="271.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.7" lower_limit="321.0" upper_limit="453.8"/>
                    <measurement group_id="O2" value="334.8" lower_limit="287.0" upper_limit="390.6"/>
                    <measurement group_id="O3" value="450.1" lower_limit="371.5" upper_limit="545.4"/>
                    <measurement group_id="O4" value="483.7" lower_limit="412.5" upper_limit="567.2"/>
                    <measurement group_id="O5" value="309.9" lower_limit="267.7" upper_limit="358.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.7" lower_limit="236.5" upper_limit="352.4"/>
                    <measurement group_id="O2" value="261.3" lower_limit="222.9" upper_limit="306.4"/>
                    <measurement group_id="O3" value="275.5" lower_limit="231.1" upper_limit="328.6"/>
                    <measurement group_id="O4" value="336.5" lower_limit="285.5" upper_limit="396.7"/>
                    <measurement group_id="O5" value="242.9" lower_limit="204.9" upper_limit="287.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.0" lower_limit="202.6" upper_limit="293.7"/>
                    <measurement group_id="O2" value="205.4" lower_limit="175.5" upper_limit="240.5"/>
                    <measurement group_id="O3" value="228.2" lower_limit="193.8" upper_limit="268.5"/>
                    <measurement group_id="O4" value="266.7" lower_limit="228.6" upper_limit="311.1"/>
                    <measurement group_id="O5" value="202.2" lower_limit="172.4" upper_limit="237.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.6" lower_limit="228.4" upper_limit="357.1"/>
                    <measurement group_id="O3" value="264.2" lower_limit="218.9" upper_limit="318.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.9" lower_limit="275.4" upper_limit="449.7"/>
                    <measurement group_id="O3" value="286.0" lower_limit="236.0" upper_limit="346.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.1" lower_limit="323.9" upper_limit="499.2"/>
                    <measurement group_id="O3" value="341.2" lower_limit="281.0" upper_limit="414.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.3" lower_limit="339.6" upper_limit="530.3"/>
                    <measurement group_id="O3" value="358.6" lower_limit="296.9" upper_limit="433.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.9" lower_limit="231.3" upper_limit="358.4"/>
                    <measurement group_id="O3" value="235.9" lower_limit="195.6" upper_limit="284.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.8" lower_limit="312.0" upper_limit="527.7"/>
                    <measurement group_id="O3" value="333.9" lower_limit="271.4" upper_limit="411.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.2" lower_limit="235.1" upper_limit="373.1"/>
                    <measurement group_id="O3" value="258.1" lower_limit="210.6" upper_limit="316.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by PRNT (Subtype A)</title>
        <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by PRNT (Subtype A)</title>
          <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype A). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="4.5" upper_limit="19.2"/>
                    <measurement group_id="O2" value="9.2" lower_limit="4.1" upper_limit="17.3"/>
                    <measurement group_id="O3" value="27.8" lower_limit="18.3" upper_limit="39.1"/>
                    <measurement group_id="O4" value="23.3" lower_limit="15.1" upper_limit="33.4"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.8" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="6.6" upper_limit="23.2"/>
                    <measurement group_id="O2" value="11.9" lower_limit="5.9" upper_limit="20.8"/>
                    <measurement group_id="O3" value="25.6" lower_limit="16.4" upper_limit="36.8"/>
                    <measurement group_id="O4" value="8.9" lower_limit="3.9" upper_limit="16.8"/>
                    <measurement group_id="O5" value="1.2" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="3.8" upper_limit="18.1"/>
                    <measurement group_id="O2" value="15.5" lower_limit="8.5" upper_limit="25.0"/>
                    <measurement group_id="O3" value="19.2" lower_limit="11.2" upper_limit="29.7"/>
                    <measurement group_id="O4" value="15.6" lower_limit="8.8" upper_limit="24.7"/>
                    <measurement group_id="O5" value="4.9" lower_limit="1.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="2.9" upper_limit="16.2"/>
                    <measurement group_id="O2" value="10.6" lower_limit="5.0" upper_limit="19.2"/>
                    <measurement group_id="O3" value="15.2" lower_limit="8.1" upper_limit="25.0"/>
                    <measurement group_id="O4" value="14.6" lower_limit="8.0" upper_limit="23.7"/>
                    <measurement group_id="O5" value="1.2" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="14.3" upper_limit="34.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="16.4" upper_limit="35.4"/>
                    <measurement group_id="O3" value="41.3" lower_limit="30.4" upper_limit="52.8"/>
                    <measurement group_id="O4" value="34.4" lower_limit="24.7" upper_limit="45.2"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="3.7" upper_limit="17.8"/>
                    <measurement group_id="O2" value="8.3" lower_limit="3.4" upper_limit="16.4"/>
                    <measurement group_id="O3" value="10.4" lower_limit="4.6" upper_limit="19.4"/>
                    <measurement group_id="O4" value="10.1" lower_limit="4.7" upper_limit="18.3"/>
                    <measurement group_id="O5" value="4.9" lower_limit="1.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="7.2" lower_limit="2.7" upper_limit="15.1"/>
                    <measurement group_id="O3" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O4" value="2.3" lower_limit="0.3" upper_limit="8.0"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.8" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="7.2" upper_limit="32.1"/>
                    <measurement group_id="O3" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="8.8" upper_limit="34.9"/>
                    <measurement group_id="O3" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="10.6" upper_limit="37.6"/>
                    <measurement group_id="O3" value="15.6" lower_limit="6.5" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.1" upper_limit="12.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="10.6" upper_limit="37.6"/>
                    <measurement group_id="O3" value="13.3" lower_limit="5.1" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.1" upper_limit="12.9"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT (Subtype B) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT (Subtype B) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '10' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.3" lower_limit="332.0" upper_limit="542.2"/>
                    <measurement group_id="O2" value="364.9" lower_limit="285.6" upper_limit="466.2"/>
                    <measurement group_id="O3" value="426.9" lower_limit="331.7" upper_limit="549.4"/>
                    <measurement group_id="O4" value="498.6" lower_limit="395.6" upper_limit="628.5"/>
                    <measurement group_id="O5" value="477.5" lower_limit="361.3" upper_limit="630.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517.7" lower_limit="407.4" upper_limit="657.9"/>
                    <measurement group_id="O2" value="464.5" lower_limit="363.7" upper_limit="593.3"/>
                    <measurement group_id="O3" value="688.6" lower_limit="528.6" upper_limit="896.9"/>
                    <measurement group_id="O4" value="638.2" lower_limit="510.9" upper_limit="797.3"/>
                    <measurement group_id="O5" value="441.4" lower_limit="331.6" upper_limit="587.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485.8" lower_limit="385.9" upper_limit="611.4"/>
                    <measurement group_id="O2" value="458.8" lower_limit="355.3" upper_limit="592.6"/>
                    <measurement group_id="O3" value="635.9" lower_limit="490.6" upper_limit="824.1"/>
                    <measurement group_id="O4" value="570.0" lower_limit="453.6" upper_limit="716.3"/>
                    <measurement group_id="O5" value="431.5" lower_limit="325.3" upper_limit="572.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506.1" lower_limit="395.0" upper_limit="648.4"/>
                    <measurement group_id="O2" value="507.4" lower_limit="396.4" upper_limit="649.6"/>
                    <measurement group_id="O3" value="615.1" lower_limit="468.9" upper_limit="806.8"/>
                    <measurement group_id="O4" value="674.3" lower_limit="544.9" upper_limit="834.4"/>
                    <measurement group_id="O5" value="454.0" lower_limit="340.7" upper_limit="605.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.0" lower_limit="398.4" upper_limit="650.5"/>
                    <measurement group_id="O2" value="483.5" lower_limit="379.5" upper_limit="615.9"/>
                    <measurement group_id="O3" value="670.1" lower_limit="505.4" upper_limit="888.5"/>
                    <measurement group_id="O4" value="610.2" lower_limit="492.5" upper_limit="756.0"/>
                    <measurement group_id="O5" value="465.3" lower_limit="351.8" upper_limit="615.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672.2" lower_limit="531.5" upper_limit="850.2"/>
                    <measurement group_id="O2" value="639.7" lower_limit="503.1" upper_limit="813.3"/>
                    <measurement group_id="O3" value="932.3" lower_limit="702.7" upper_limit="1236.9"/>
                    <measurement group_id="O4" value="858.0" lower_limit="689.2" upper_limit="1068.0"/>
                    <measurement group_id="O5" value="614.6" lower_limit="462.0" upper_limit="817.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577.8" lower_limit="457.1" upper_limit="730.5"/>
                    <measurement group_id="O2" value="505.7" lower_limit="403.4" upper_limit="634.0"/>
                    <measurement group_id="O3" value="639.0" lower_limit="499.4" upper_limit="817.7"/>
                    <measurement group_id="O4" value="635.6" lower_limit="517.1" upper_limit="781.1"/>
                    <measurement group_id="O5" value="515.6" lower_limit="394.3" upper_limit="674.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570.6" lower_limit="453.7" upper_limit="717.6"/>
                    <measurement group_id="O2" value="458.1" lower_limit="361.9" upper_limit="579.8"/>
                    <measurement group_id="O3" value="606.1" lower_limit="479.9" upper_limit="765.3"/>
                    <measurement group_id="O4" value="583.2" lower_limit="471.2" upper_limit="721.9"/>
                    <measurement group_id="O5" value="518.1" lower_limit="398.7" upper_limit="673.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="561.0" lower_limit="395.7" upper_limit="795.3"/>
                    <measurement group_id="O3" value="584.5" lower_limit="423.4" upper_limit="806.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894.1" lower_limit="656.2" upper_limit="1218.2"/>
                    <measurement group_id="O3" value="954.8" lower_limit="702.8" upper_limit="1297.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.7" lower_limit="561.4" upper_limit="1033.4"/>
                    <measurement group_id="O3" value="804.2" lower_limit="585.9" upper_limit="1103.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.5" lower_limit="730.1" upper_limit="1349.2"/>
                    <measurement group_id="O3" value="1031.2" lower_limit="755.2" upper_limit="1407.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.2" lower_limit="470.4" upper_limit="849.5"/>
                    <measurement group_id="O3" value="686.7" lower_limit="509.1" upper_limit="926.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759.0" lower_limit="561.3" upper_limit="1026.5"/>
                    <measurement group_id="O3" value="782.3" lower_limit="581.8" upper_limit="1051.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.7" lower_limit="448.8" upper_limit="801.3"/>
                    <measurement group_id="O3" value="669.4" lower_limit="493.7" upper_limit="907.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by PRNT (Subtype B)</title>
        <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by PRNT (Subtype B)</title>
          <description>Response rate based on RSV-specific Plaque Reduction Neutralization Test (PRNT; against subtype B). Response is defined as the appearance of antibody titers ≥ detection limit (20) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="6.3" upper_limit="22.3"/>
                    <measurement group_id="O2" value="18.4" lower_limit="10.9" upper_limit="28.1"/>
                    <measurement group_id="O3" value="26.6" lower_limit="17.3" upper_limit="37.7"/>
                    <measurement group_id="O4" value="14.4" lower_limit="7.9" upper_limit="23.4"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.8" upper_limit="18.3"/>
                    <measurement group_id="O2" value="14.3" lower_limit="7.6" upper_limit="23.6"/>
                    <measurement group_id="O3" value="29.5" lower_limit="19.7" upper_limit="40.9"/>
                    <measurement group_id="O4" value="11.1" lower_limit="5.5" upper_limit="19.5"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4.7" upper_limit="19.7"/>
                    <measurement group_id="O2" value="21.4" lower_limit="13.2" upper_limit="31.7"/>
                    <measurement group_id="O3" value="24.4" lower_limit="15.3" upper_limit="35.4"/>
                    <measurement group_id="O4" value="21.1" lower_limit="13.2" upper_limit="31.0"/>
                    <measurement group_id="O5" value="4.9" lower_limit="1.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="8.3" upper_limit="25.6"/>
                    <measurement group_id="O2" value="11.8" lower_limit="5.8" upper_limit="20.6"/>
                    <measurement group_id="O3" value="26.6" lower_limit="17.3" upper_limit="37.7"/>
                    <measurement group_id="O4" value="14.6" lower_limit="8.0" upper_limit="23.7"/>
                    <measurement group_id="O5" value="2.5" lower_limit="0.3" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="16.4" upper_limit="36.8"/>
                    <measurement group_id="O2" value="34.1" lower_limit="24.3" upper_limit="45.0"/>
                    <measurement group_id="O3" value="45.0" lower_limit="33.8" upper_limit="56.5"/>
                    <measurement group_id="O4" value="34.4" lower_limit="24.7" upper_limit="45.2"/>
                    <measurement group_id="O5" value="9.8" lower_limit="4.3" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="5.5" upper_limit="21.0"/>
                    <measurement group_id="O2" value="20.2" lower_limit="12.3" upper_limit="30.4"/>
                    <measurement group_id="O3" value="22.1" lower_limit="13.4" upper_limit="33.0"/>
                    <measurement group_id="O4" value="13.5" lower_limit="7.2" upper_limit="22.4"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.8" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="11.6" upper_limit="30.8"/>
                    <measurement group_id="O2" value="13.3" lower_limit="6.8" upper_limit="22.5"/>
                    <measurement group_id="O3" value="21.1" lower_limit="12.5" upper_limit="31.9"/>
                    <measurement group_id="O4" value="11.4" lower_limit="5.6" upper_limit="19.9"/>
                    <measurement group_id="O5" value="11.0" lower_limit="5.1" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O3" value="33.3" lower_limit="20.0" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="7.2" upper_limit="32.1"/>
                    <measurement group_id="O3" value="20.0" lower_limit="9.6" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O3" value="35.6" lower_limit="21.9" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="5.6" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="8.8" upper_limit="34.9"/>
                    <measurement group_id="O3" value="17.8" lower_limit="8.0" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="0.6" upper_limit="16.5"/>
                    <measurement group_id="O3" value="9.1" lower_limit="2.5" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA (IgG) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '31.5' (i.e. 1/2 DL)</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA (IgG) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '31.5' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1578.4" lower_limit="1394.0" upper_limit="1787.3"/>
                    <measurement group_id="O2" value="1488.6" lower_limit="1322.4" upper_limit="1675.8"/>
                    <measurement group_id="O3" value="1636.1" lower_limit="1421.9" upper_limit="1882.6"/>
                    <measurement group_id="O4" value="1819.5" lower_limit="1595.2" upper_limit="2075.2"/>
                    <measurement group_id="O5" value="1672.2" lower_limit="1480.7" upper_limit="1888.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2506.9" lower_limit="2221.3" upper_limit="2829.3"/>
                    <measurement group_id="O2" value="2460.0" lower_limit="2172.9" upper_limit="2785.0"/>
                    <measurement group_id="O3" value="3773.6" lower_limit="3212.8" upper_limit="4432.4"/>
                    <measurement group_id="O4" value="3639.5" lower_limit="3212.7" upper_limit="4122.9"/>
                    <measurement group_id="O5" value="1674.3" lower_limit="1486.8" upper_limit="1885.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2599.9" lower_limit="2299.0" upper_limit="2940.2"/>
                    <measurement group_id="O2" value="2559.9" lower_limit="2233.4" upper_limit="2934.2"/>
                    <measurement group_id="O3" value="3884.6" lower_limit="3336.2" upper_limit="4523.2"/>
                    <measurement group_id="O4" value="3697.0" lower_limit="3257.6" upper_limit="4195.7"/>
                    <measurement group_id="O5" value="1747.3" lower_limit="1550.1" upper_limit="1969.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2671.0" lower_limit="2365.5" upper_limit="3015.9"/>
                    <measurement group_id="O2" value="2964.1" lower_limit="2601.4" upper_limit="3377.2"/>
                    <measurement group_id="O3" value="3864.3" lower_limit="3348.1" upper_limit="4460.2"/>
                    <measurement group_id="O4" value="4270.0" lower_limit="3753.4" upper_limit="4857.7"/>
                    <measurement group_id="O5" value="1766.6" lower_limit="1536.0" upper_limit="2031.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2653.4" lower_limit="2309.5" upper_limit="3048.5"/>
                    <measurement group_id="O2" value="2960.1" lower_limit="2592.8" upper_limit="3379.4"/>
                    <measurement group_id="O3" value="3773.6" lower_limit="3278.4" upper_limit="4343.6"/>
                    <measurement group_id="O4" value="4283.2" lower_limit="3790.3" upper_limit="4840.2"/>
                    <measurement group_id="O5" value="1844.6" lower_limit="1603.1" upper_limit="2122.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3266.2" lower_limit="2878.5" upper_limit="3706.1"/>
                    <measurement group_id="O2" value="3412.2" lower_limit="3001.8" upper_limit="3878.8"/>
                    <measurement group_id="O3" value="4824.0" lower_limit="4161.9" upper_limit="5591.4"/>
                    <measurement group_id="O4" value="5061.4" lower_limit="4493.0" upper_limit="5701.8"/>
                    <measurement group_id="O5" value="2207.2" lower_limit="1926.4" upper_limit="2528.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2833.4" lower_limit="2489.8" upper_limit="3224.3"/>
                    <measurement group_id="O2" value="2965.0" lower_limit="2609.3" upper_limit="3369.3"/>
                    <measurement group_id="O3" value="3294.5" lower_limit="2906.5" upper_limit="3734.2"/>
                    <measurement group_id="O4" value="3950.8" lower_limit="3519.2" upper_limit="4435.3"/>
                    <measurement group_id="O5" value="2117.1" lower_limit="1815.8" upper_limit="2468.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2162.3" lower_limit="1885.3" upper_limit="2480.2"/>
                    <measurement group_id="O2" value="2107.5" lower_limit="1825.7" upper_limit="2432.7"/>
                    <measurement group_id="O3" value="2796.5" lower_limit="2416.3" upper_limit="3236.6"/>
                    <measurement group_id="O4" value="3023.4" lower_limit="2682.7" upper_limit="3407.3"/>
                    <measurement group_id="O5" value="1777.6" lower_limit="1513.1" upper_limit="2088.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2501.8" lower_limit="2145.8" upper_limit="2916.8"/>
                    <measurement group_id="O3" value="2816.4" lower_limit="2406.9" upper_limit="3295.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3878.2" lower_limit="3263.2" upper_limit="4609.1"/>
                    <measurement group_id="O3" value="4261.7" lower_limit="3532.7" upper_limit="5141.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4139.6" lower_limit="3466.7" upper_limit="4943.2"/>
                    <measurement group_id="O3" value="4368.3" lower_limit="3622.1" upper_limit="5268.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4445.5" lower_limit="3730.1" upper_limit="5298.1"/>
                    <measurement group_id="O3" value="4788.9" lower_limit="3970.0" upper_limit="5776.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3031.5" lower_limit="2489.7" upper_limit="3691.2"/>
                    <measurement group_id="O3" value="3250.5" lower_limit="2652.3" upper_limit="3983.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2568.9" lower_limit="2169.2" upper_limit="3042.3"/>
                    <measurement group_id="O3" value="2754.0" lower_limit="2335.0" upper_limit="3248.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2083.1" lower_limit="1761.6" upper_limit="2463.4"/>
                    <measurement group_id="O3" value="2260.0" lower_limit="1893.7" upper_limit="2697.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by IgG ELISA</title>
        <description>Response rate based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (63) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by IgG ELISA</title>
          <description>Response rate based on RSV-specific Immunoglobulin G (IgG) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (63) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="13.2" upper_limit="32.6"/>
                    <measurement group_id="O2" value="19.5" lower_limit="11.8" upper_limit="29.4"/>
                    <measurement group_id="O3" value="51.9" lower_limit="40.4" upper_limit="63.3"/>
                    <measurement group_id="O4" value="44.4" lower_limit="34.0" upper_limit="55.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="14.9" upper_limit="35.3"/>
                    <measurement group_id="O2" value="27.4" lower_limit="18.2" upper_limit="38.2"/>
                    <measurement group_id="O3" value="60.3" lower_limit="48.5" upper_limit="71.2"/>
                    <measurement group_id="O4" value="46.7" lower_limit="36.1" upper_limit="57.5"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="19.1" upper_limit="40.5"/>
                    <measurement group_id="O2" value="39.3" lower_limit="28.8" upper_limit="50.5"/>
                    <measurement group_id="O3" value="55.1" lower_limit="43.4" upper_limit="66.4"/>
                    <measurement group_id="O4" value="58.9" lower_limit="48.0" upper_limit="69.2"/>
                    <measurement group_id="O5" value="2.5" lower_limit="0.3" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="20.0" upper_limit="41.4"/>
                    <measurement group_id="O2" value="40.0" lower_limit="29.5" upper_limit="51.2"/>
                    <measurement group_id="O3" value="54.4" lower_limit="42.8" upper_limit="65.7"/>
                    <measurement group_id="O4" value="59.6" lower_limit="48.6" upper_limit="69.8"/>
                    <measurement group_id="O5" value="1.2" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="31.2" upper_limit="54.0"/>
                    <measurement group_id="O2" value="53.4" lower_limit="42.5" upper_limit="64.1"/>
                    <measurement group_id="O3" value="70.0" lower_limit="58.7" upper_limit="79.7"/>
                    <measurement group_id="O4" value="71.1" lower_limit="60.6" upper_limit="80.2"/>
                    <measurement group_id="O5" value="4.9" lower_limit="1.3" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="20.0" upper_limit="41.4"/>
                    <measurement group_id="O2" value="44.0" lower_limit="33.2" upper_limit="55.3"/>
                    <measurement group_id="O3" value="45.5" lower_limit="34.1" upper_limit="57.2"/>
                    <measurement group_id="O4" value="51.7" lower_limit="40.8" upper_limit="62.4"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.8" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="6.6" upper_limit="23.2"/>
                    <measurement group_id="O2" value="14.5" lower_limit="7.7" upper_limit="23.9"/>
                    <measurement group_id="O3" value="28.9" lower_limit="19.1" upper_limit="40.5"/>
                    <measurement group_id="O4" value="26.1" lower_limit="17.3" upper_limit="36.6"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="10.6" upper_limit="37.6"/>
                    <measurement group_id="O3" value="22.2" lower_limit="11.2" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="8.8" upper_limit="34.9"/>
                    <measurement group_id="O3" value="17.8" lower_limit="8.0" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="12.4" upper_limit="40.3"/>
                    <measurement group_id="O3" value="28.9" lower_limit="16.4" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="2.7" upper_limit="23.1"/>
                    <measurement group_id="O3" value="13.3" lower_limit="5.1" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="0.6" upper_limit="16.5"/>
                    <measurement group_id="O3" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="8.6"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA (IgA) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '50' (i.e. 1/2 DL)</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA (IgA) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '50' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.7" lower_limit="453.0" upper_limit="747.1"/>
                    <measurement group_id="O2" value="591.1" lower_limit="475.1" upper_limit="735.3"/>
                    <measurement group_id="O3" value="776.3" lower_limit="614.9" upper_limit="980.0"/>
                    <measurement group_id="O4" value="623.3" lower_limit="494.9" upper_limit="785.0"/>
                    <measurement group_id="O5" value="585.4" lower_limit="451.7" upper_limit="758.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1377.7" lower_limit="1091.6" upper_limit="1738.7"/>
                    <measurement group_id="O2" value="1373.3" lower_limit="1067.2" upper_limit="1767.1"/>
                    <measurement group_id="O3" value="2593.6" lower_limit="2017.9" upper_limit="3333.6"/>
                    <measurement group_id="O4" value="1922.8" lower_limit="1515.9" upper_limit="2439.0"/>
                    <measurement group_id="O5" value="619.8" lower_limit="487.6" upper_limit="787.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1061.3" lower_limit="813.6" upper_limit="1384.5"/>
                    <measurement group_id="O2" value="1120.8" lower_limit="858.2" upper_limit="1463.8"/>
                    <measurement group_id="O3" value="1763.0" lower_limit="1370.6" upper_limit="2267.7"/>
                    <measurement group_id="O4" value="1378.1" lower_limit="1091.0" upper_limit="1740.7"/>
                    <measurement group_id="O5" value="614.9" lower_limit="478.3" upper_limit="790.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1001.3" lower_limit="778.6" upper_limit="1287.7"/>
                    <measurement group_id="O2" value="1248.3" lower_limit="958.1" upper_limit="1626.4"/>
                    <measurement group_id="O3" value="1538.8" lower_limit="1205.5" upper_limit="1964.1"/>
                    <measurement group_id="O4" value="1592.9" lower_limit="1279.9" upper_limit="1982.4"/>
                    <measurement group_id="O5" value="608.8" lower_limit="462.1" upper_limit="802.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="887.3" lower_limit="687.6" upper_limit="1145.1"/>
                    <measurement group_id="O2" value="1045.1" lower_limit="808.6" upper_limit="1350.9"/>
                    <measurement group_id="O3" value="1459.2" lower_limit="1137.2" upper_limit="1872.4"/>
                    <measurement group_id="O4" value="1367.3" lower_limit="1071.6" upper_limit="1744.6"/>
                    <measurement group_id="O5" value="590.8" lower_limit="447.9" upper_limit="779.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1511.0" lower_limit="1195.9" upper_limit="1909.1"/>
                    <measurement group_id="O2" value="1696.5" lower_limit="1336.9" upper_limit="2152.8"/>
                    <measurement group_id="O3" value="2795.1" lower_limit="2173.6" upper_limit="3594.1"/>
                    <measurement group_id="O4" value="2331.1" lower_limit="1860.6" upper_limit="2920.8"/>
                    <measurement group_id="O5" value="777.0" lower_limit="601.7" upper_limit="1003.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.3" lower_limit="580.6" upper_limit="956.7"/>
                    <measurement group_id="O2" value="709.8" lower_limit="550.2" upper_limit="915.5"/>
                    <measurement group_id="O3" value="1001.6" lower_limit="786.2" upper_limit="1276.1"/>
                    <measurement group_id="O4" value="933.2" lower_limit="754.0" upper_limit="1155.1"/>
                    <measurement group_id="O5" value="573.8" lower_limit="439.6" upper_limit="748.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675.3" lower_limit="531.3" upper_limit="858.4"/>
                    <measurement group_id="O2" value="743.5" lower_limit="568.8" upper_limit="971.9"/>
                    <measurement group_id="O3" value="1089.5" lower_limit="887.7" upper_limit="1337.2"/>
                    <measurement group_id="O4" value="970.3" lower_limit="796.6" upper_limit="1181.8"/>
                    <measurement group_id="O5" value="676.3" lower_limit="534.5" upper_limit="855.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="627.3" lower_limit="437.3" upper_limit="899.8"/>
                    <measurement group_id="O3" value="719.4" lower_limit="540.8" upper_limit="957.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1235.2" lower_limit="864.0" upper_limit="1766.0"/>
                    <measurement group_id="O3" value="1480.5" lower_limit="1153.1" upper_limit="1900.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941.3" lower_limit="658.9" upper_limit="1344.7"/>
                    <measurement group_id="O3" value="1099.0" lower_limit="829.3" upper_limit="1456.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1261.3" lower_limit="887.5" upper_limit="1792.5"/>
                    <measurement group_id="O3" value="1511.0" lower_limit="1175.0" upper_limit="1943.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734.4" lower_limit="513.4" upper_limit="1050.5"/>
                    <measurement group_id="O3" value="853.3" lower_limit="629.1" upper_limit="1157.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711.0" lower_limit="517.8" upper_limit="976.2"/>
                    <measurement group_id="O3" value="838.1" lower_limit="649.2" upper_limit="1081.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="619.1" lower_limit="448.7" upper_limit="854.3"/>
                    <measurement group_id="O3" value="716.7" lower_limit="542.0" upper_limit="947.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by IgA ELISA</title>
        <description>Response rate based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (100) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
        <time_frame>within 108 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by IgA ELISA</title>
          <description>Response rate based on RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (100) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="38.5" upper_limit="61.5"/>
                    <measurement group_id="O2" value="51.7" lower_limit="40.8" upper_limit="62.6"/>
                    <measurement group_id="O3" value="68.4" lower_limit="56.9" upper_limit="78.4"/>
                    <measurement group_id="O4" value="70.0" lower_limit="59.4" upper_limit="79.2"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="21.7" upper_limit="43.8"/>
                    <measurement group_id="O2" value="36.9" lower_limit="26.6" upper_limit="48.1"/>
                    <measurement group_id="O3" value="48.7" lower_limit="37.2" upper_limit="60.3"/>
                    <measurement group_id="O4" value="52.2" lower_limit="41.4" upper_limit="62.9"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="19.1" upper_limit="40.5"/>
                    <measurement group_id="O2" value="46.4" lower_limit="35.5" upper_limit="57.6"/>
                    <measurement group_id="O3" value="44.9" lower_limit="33.6" upper_limit="56.6"/>
                    <measurement group_id="O4" value="62.2" lower_limit="51.4" upper_limit="72.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.8" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="15.6" upper_limit="35.8"/>
                    <measurement group_id="O2" value="37.6" lower_limit="27.4" upper_limit="48.8"/>
                    <measurement group_id="O3" value="36.7" lower_limit="26.1" upper_limit="48.3"/>
                    <measurement group_id="O4" value="51.7" lower_limit="40.8" upper_limit="62.4"/>
                    <measurement group_id="O5" value="4.9" lower_limit="1.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="42.2" upper_limit="65.2"/>
                    <measurement group_id="O2" value="69.3" lower_limit="58.6" upper_limit="78.7"/>
                    <measurement group_id="O3" value="72.5" lower_limit="61.4" upper_limit="81.9"/>
                    <measurement group_id="O4" value="77.8" lower_limit="67.8" upper_limit="85.9"/>
                    <measurement group_id="O5" value="14.6" lower_limit="7.8" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="7.4" upper_limit="24.1"/>
                    <measurement group_id="O2" value="14.3" lower_limit="7.6" upper_limit="23.6"/>
                    <measurement group_id="O3" value="28.6" lower_limit="18.8" upper_limit="40.0"/>
                    <measurement group_id="O4" value="22.5" lower_limit="14.3" upper_limit="32.6"/>
                    <measurement group_id="O5" value="8.6" lower_limit="3.5" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.8" upper_limit="18.3"/>
                    <measurement group_id="O2" value="22.9" lower_limit="14.4" upper_limit="33.4"/>
                    <measurement group_id="O3" value="27.6" lower_limit="18.0" upper_limit="39.1"/>
                    <measurement group_id="O4" value="30.7" lower_limit="21.3" upper_limit="41.4"/>
                    <measurement group_id="O5" value="14.6" lower_limit="7.8" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O3" value="44.4" lower_limit="29.6" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="7.2" upper_limit="32.1"/>
                    <measurement group_id="O3" value="24.4" lower_limit="12.9" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O3" value="44.4" lower_limit="29.6" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="1.5" upper_limit="19.9"/>
                    <measurement group_id="O3" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="1.5" upper_limit="19.9"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (Booster Follow-Up 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.1" upper_limit="12.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA (Mucosal IgA) GMT</title>
        <description>Geometric Mean Titers (GMTs) based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '1' (i.e. 1/2 DL)</description>
        <time_frame>within 82 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA (Mucosal IgA) GMT</title>
          <description>Geometric Mean Titers (GMTs) based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Titers below the detection limit (DL) are included with a value of '1' (i.e. 1/2 DL)</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="9.8" upper_limit="14.6"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.4" upper_limit="12.5"/>
                    <measurement group_id="O3" value="11.9" lower_limit="9.7" upper_limit="14.6"/>
                    <measurement group_id="O4" value="13.7" lower_limit="11.4" upper_limit="16.6"/>
                    <measurement group_id="O5" value="12.3" lower_limit="10.1" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.7" upper_limit="17.0"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.3" upper_limit="14.3"/>
                    <measurement group_id="O3" value="15.7" lower_limit="13.3" upper_limit="18.5"/>
                    <measurement group_id="O4" value="15.2" lower_limit="12.6" upper_limit="18.3"/>
                    <measurement group_id="O5" value="12.0" lower_limit="9.9" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="11.4" upper_limit="16.1"/>
                    <measurement group_id="O2" value="13.1" lower_limit="11.2" upper_limit="15.3"/>
                    <measurement group_id="O3" value="14.1" lower_limit="11.9" upper_limit="16.7"/>
                    <measurement group_id="O4" value="15.0" lower_limit="12.6" upper_limit="17.8"/>
                    <measurement group_id="O5" value="12.2" lower_limit="10.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="10.9" upper_limit="15.7"/>
                    <measurement group_id="O2" value="13.4" lower_limit="11.3" upper_limit="15.8"/>
                    <measurement group_id="O3" value="13.2" lower_limit="11.0" upper_limit="15.7"/>
                    <measurement group_id="O4" value="15.1" lower_limit="12.7" upper_limit="18.1"/>
                    <measurement group_id="O5" value="12.4" lower_limit="10.1" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="11.4" upper_limit="15.9"/>
                    <measurement group_id="O2" value="12.6" lower_limit="10.9" upper_limit="14.6"/>
                    <measurement group_id="O3" value="13.1" lower_limit="10.8" upper_limit="15.7"/>
                    <measurement group_id="O4" value="14.6" lower_limit="12.1" upper_limit="17.5"/>
                    <measurement group_id="O5" value="11.2" lower_limit="9.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="15.8" upper_limit="21.9"/>
                    <measurement group_id="O2" value="18.0" lower_limit="15.3" upper_limit="21.1"/>
                    <measurement group_id="O3" value="20.5" lower_limit="17.5" upper_limit="24.0"/>
                    <measurement group_id="O4" value="21.4" lower_limit="18.0" upper_limit="25.4"/>
                    <measurement group_id="O5" value="17.3" lower_limit="14.4" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="10.7" upper_limit="15.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="10.0" upper_limit="14.0"/>
                    <measurement group_id="O3" value="13.2" lower_limit="10.9" upper_limit="16.2"/>
                    <measurement group_id="O4" value="13.0" lower_limit="10.7" upper_limit="15.8"/>
                    <measurement group_id="O5" value="11.7" lower_limit="9.7" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="11.2" upper_limit="15.3"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.3" upper_limit="14.2"/>
                    <measurement group_id="O3" value="13.4" lower_limit="11.0" upper_limit="16.2"/>
                    <measurement group_id="O4" value="13.6" lower_limit="11.4" upper_limit="16.2"/>
                    <measurement group_id="O5" value="13.1" lower_limit="10.6" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="12.8" upper_limit="19.0"/>
                    <measurement group_id="O3" value="11.9" lower_limit="9.5" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="12.0" upper_limit="18.8"/>
                    <measurement group_id="O3" value="14.6" lower_limit="11.6" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="13.4" upper_limit="20.1"/>
                    <measurement group_id="O3" value="13.8" lower_limit="11.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="15.1" upper_limit="21.9"/>
                    <measurement group_id="O3" value="16.5" lower_limit="13.4" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="13.8" upper_limit="20.6"/>
                    <measurement group_id="O3" value="13.3" lower_limit="10.5" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="9.6" upper_limit="16.6"/>
                    <measurement group_id="O3" value="8.4" lower_limit="6.5" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by Mucosal IgA ELISA</title>
        <description>Response rate based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (2) for initially negative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
        <time_frame>within 82 weeks</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by Mucosal IgA ELISA</title>
          <description>Response rate based on mucosal RSV-specific Immunoglobulin A (IgA) Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (2) for initially negative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Individual peak response rate is based on the maximum post-Baseline antibody titer up to the end of the respective active trial phase i.e., within 8 weeks for the main study and within 4 weeks for the booster substudy. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="5.7" upper_limit="21.8"/>
                    <measurement group_id="O2" value="14.5" lower_limit="7.7" upper_limit="23.9"/>
                    <measurement group_id="O3" value="22.4" lower_limit="13.6" upper_limit="33.4"/>
                    <measurement group_id="O4" value="12.5" lower_limit="6.4" upper_limit="21.3"/>
                    <measurement group_id="O5" value="5.1" lower_limit="1.4" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="7.7" upper_limit="25.0"/>
                    <measurement group_id="O2" value="12.7" lower_limit="6.2" upper_limit="22.0"/>
                    <measurement group_id="O3" value="13.5" lower_limit="6.7" upper_limit="23.5"/>
                    <measurement group_id="O4" value="14.0" lower_limit="7.4" upper_limit="23.1"/>
                    <measurement group_id="O5" value="10.4" lower_limit="4.6" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.9" upper_limit="22.4"/>
                    <measurement group_id="O2" value="17.7" lower_limit="10.0" upper_limit="27.9"/>
                    <measurement group_id="O3" value="17.6" lower_limit="9.7" upper_limit="28.2"/>
                    <measurement group_id="O4" value="16.5" lower_limit="9.3" upper_limit="26.1"/>
                    <measurement group_id="O5" value="8.1" lower_limit="3.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="6.6" upper_limit="23.2"/>
                    <measurement group_id="O2" value="16.5" lower_limit="9.1" upper_limit="26.5"/>
                    <measurement group_id="O3" value="20.0" lower_limit="11.6" upper_limit="30.8"/>
                    <measurement group_id="O4" value="11.9" lower_limit="5.9" upper_limit="20.8"/>
                    <measurement group_id="O5" value="6.7" lower_limit="2.2" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="15.8" upper_limit="36.3"/>
                    <measurement group_id="O2" value="34.5" lower_limit="24.6" upper_limit="45.4"/>
                    <measurement group_id="O3" value="33.3" lower_limit="23.1" upper_limit="44.9"/>
                    <measurement group_id="O4" value="28.4" lower_limit="19.3" upper_limit="39.0"/>
                    <measurement group_id="O5" value="17.9" lower_limit="10.2" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="5.8" upper_limit="22.1"/>
                    <measurement group_id="O2" value="15.9" lower_limit="8.7" upper_limit="25.6"/>
                    <measurement group_id="O3" value="18.7" lower_limit="10.6" upper_limit="29.3"/>
                    <measurement group_id="O4" value="11.9" lower_limit="5.9" upper_limit="20.8"/>
                    <measurement group_id="O5" value="7.7" lower_limit="2.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.9" upper_limit="22.4"/>
                    <measurement group_id="O2" value="12.5" lower_limit="6.2" upper_limit="21.8"/>
                    <measurement group_id="O3" value="20.0" lower_limit="11.6" upper_limit="30.8"/>
                    <measurement group_id="O4" value="10.7" lower_limit="5.0" upper_limit="19.4"/>
                    <measurement group_id="O5" value="11.5" lower_limit="5.4" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="4.1" upper_limit="26.2"/>
                    <measurement group_id="O3" value="7.1" lower_limit="1.5" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="4.1" upper_limit="26.2"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="5.4" upper_limit="28.5"/>
                    <measurement group_id="O3" value="9.5" lower_limit="2.7" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="1.5" upper_limit="19.9"/>
                    <measurement group_id="O3" value="9.5" lower_limit="2.7" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IFN-g, Peptide Pool: F) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IFN-g, Peptide Pool: F) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.2" lower_limit="210.1" upper_limit="381.7"/>
                    <measurement group_id="O2" value="141.3" lower_limit="88.9" upper_limit="224.6"/>
                    <measurement group_id="O3" value="142.6" lower_limit="85.4" upper_limit="238.3"/>
                    <measurement group_id="O4" value="245.8" lower_limit="162.2" upper_limit="372.2"/>
                    <measurement group_id="O5" value="138.9" lower_limit="83.8" upper_limit="230.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="683.3" lower_limit="511.3" upper_limit="913.2"/>
                    <measurement group_id="O2" value="662.9" lower_limit="475.7" upper_limit="923.8"/>
                    <measurement group_id="O3" value="940.4" lower_limit="719.8" upper_limit="1228.7"/>
                    <measurement group_id="O4" value="810.2" lower_limit="592.9" upper_limit="1107.1"/>
                    <measurement group_id="O5" value="117.1" lower_limit="70.6" upper_limit="194.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589.5" lower_limit="447.2" upper_limit="777.3"/>
                    <measurement group_id="O2" value="384.9" lower_limit="218.7" upper_limit="677.2"/>
                    <measurement group_id="O3" value="591.0" lower_limit="438.7" upper_limit="796.2"/>
                    <measurement group_id="O4" value="598.2" lower_limit="446.1" upper_limit="802.1"/>
                    <measurement group_id="O5" value="144.3" lower_limit="94.6" upper_limit="220.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420.1" lower_limit="291.0" upper_limit="606.4"/>
                    <measurement group_id="O2" value="353.4" lower_limit="253.1" upper_limit="493.5"/>
                    <measurement group_id="O3" value="496.4" lower_limit="353.1" upper_limit="697.7"/>
                    <measurement group_id="O4" value="608.6" lower_limit="459.2" upper_limit="806.5"/>
                    <measurement group_id="O5" value="140.9" lower_limit="84.0" upper_limit="236.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.5" lower_limit="258.6" upper_limit="595.8"/>
                    <measurement group_id="O2" value="348.9" lower_limit="218.3" upper_limit="557.7"/>
                    <measurement group_id="O3" value="502.8" lower_limit="346.8" upper_limit="728.9"/>
                    <measurement group_id="O4" value="553.1" lower_limit="428.5" upper_limit="713.9"/>
                    <measurement group_id="O5" value="122.9" lower_limit="76.3" upper_limit="197.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.6" lower_limit="190.6" upper_limit="418.9"/>
                    <measurement group_id="O3" value="378.8" lower_limit="185.6" upper_limit="773.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628.7" lower_limit="432.7" upper_limit="913.6"/>
                    <measurement group_id="O3" value="566.2" lower_limit="349.4" upper_limit="917.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514.4" lower_limit="365.5" upper_limit="723.9"/>
                    <measurement group_id="O3" value="539.7" lower_limit="325.5" upper_limit="894.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IFN-g, Peptide Pool: G(A)) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IFN-g, Peptide Pool: G(A)) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.2" lower_limit="75.3" upper_limit="205.0"/>
                    <measurement group_id="O2" value="70.2" lower_limit="44.6" upper_limit="110.4"/>
                    <measurement group_id="O3" value="66.2" lower_limit="43.0" upper_limit="101.9"/>
                    <measurement group_id="O4" value="150.7" lower_limit="101.1" upper_limit="224.6"/>
                    <measurement group_id="O5" value="88.1" lower_limit="54.5" upper_limit="142.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517.9" lower_limit="369.1" upper_limit="726.8"/>
                    <measurement group_id="O2" value="370.9" lower_limit="219.2" upper_limit="627.6"/>
                    <measurement group_id="O3" value="564.7" lower_limit="395.2" upper_limit="807.1"/>
                    <measurement group_id="O4" value="659.7" lower_limit="436.3" upper_limit="997.5"/>
                    <measurement group_id="O5" value="68.2" lower_limit="40.9" upper_limit="113.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369.3" lower_limit="245.8" upper_limit="555.0"/>
                    <measurement group_id="O2" value="190.5" lower_limit="100.6" upper_limit="360.7"/>
                    <measurement group_id="O3" value="290.0" lower_limit="169.5" upper_limit="496.1"/>
                    <measurement group_id="O4" value="432.7" lower_limit="337.0" upper_limit="555.5"/>
                    <measurement group_id="O5" value="71.2" lower_limit="41.3" upper_limit="122.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.1" lower_limit="192.2" upper_limit="382.5"/>
                    <measurement group_id="O2" value="180.9" lower_limit="104.5" upper_limit="313.0"/>
                    <measurement group_id="O3" value="209.6" lower_limit="132.1" upper_limit="332.5"/>
                    <measurement group_id="O4" value="415.7" lower_limit="298.9" upper_limit="578.1"/>
                    <measurement group_id="O5" value="68.9" lower_limit="38.3" upper_limit="124.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.8" lower_limit="139.0" upper_limit="338.1"/>
                    <measurement group_id="O2" value="185.0" lower_limit="104.3" upper_limit="328.3"/>
                    <measurement group_id="O3" value="226.6" lower_limit="152.7" upper_limit="336.4"/>
                    <measurement group_id="O4" value="373.6" lower_limit="266.6" upper_limit="523.6"/>
                    <measurement group_id="O5" value="70.4" lower_limit="42.8" upper_limit="115.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.5" lower_limit="65.0" upper_limit="246.0"/>
                    <measurement group_id="O3" value="116.1" lower_limit="58.8" upper_limit="229.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.6" lower_limit="221.2" upper_limit="773.4"/>
                    <measurement group_id="O3" value="217.4" lower_limit="99.4" upper_limit="475.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.4" lower_limit="250.5" upper_limit="589.8"/>
                    <measurement group_id="O3" value="251.7" lower_limit="150.7" upper_limit="420.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IFN-g, Peptide Pool: G(B)) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IFN-g, Peptide Pool: G(B)) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.3" lower_limit="64.6" upper_limit="191.7"/>
                    <measurement group_id="O2" value="63.4" lower_limit="35.4" upper_limit="113.3"/>
                    <measurement group_id="O3" value="56.8" lower_limit="31.5" upper_limit="102.6"/>
                    <measurement group_id="O4" value="135.5" lower_limit="83.2" upper_limit="220.7"/>
                    <measurement group_id="O5" value="73.6" lower_limit="43.6" upper_limit="124.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.6" lower_limit="243.4" upper_limit="656.1"/>
                    <measurement group_id="O2" value="306.0" lower_limit="165.9" upper_limit="564.4"/>
                    <measurement group_id="O3" value="305.6" lower_limit="165.5" upper_limit="564.2"/>
                    <measurement group_id="O4" value="613.0" lower_limit="428.7" upper_limit="876.5"/>
                    <measurement group_id="O5" value="65.6" lower_limit="40.4" upper_limit="106.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.9" lower_limit="136.5" upper_limit="450.1"/>
                    <measurement group_id="O2" value="141.4" lower_limit="73.9" upper_limit="270.7"/>
                    <measurement group_id="O3" value="181.2" lower_limit="93.2" upper_limit="352.4"/>
                    <measurement group_id="O4" value="371.5" lower_limit="269.7" upper_limit="511.7"/>
                    <measurement group_id="O5" value="71.6" lower_limit="43.8" upper_limit="117.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.9" lower_limit="115.3" upper_limit="336.2"/>
                    <measurement group_id="O2" value="184.0" lower_limit="102.6" upper_limit="330.0"/>
                    <measurement group_id="O3" value="138.8" lower_limit="73.7" upper_limit="261.6"/>
                    <measurement group_id="O4" value="406.8" lower_limit="287.9" upper_limit="574.9"/>
                    <measurement group_id="O5" value="86.6" lower_limit="47.4" upper_limit="158.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.8" lower_limit="102.9" upper_limit="307.0"/>
                    <measurement group_id="O2" value="219.0" lower_limit="114.2" upper_limit="419.8"/>
                    <measurement group_id="O3" value="128.1" lower_limit="66.4" upper_limit="247.3"/>
                    <measurement group_id="O4" value="359.7" lower_limit="257.9" upper_limit="501.5"/>
                    <measurement group_id="O5" value="77.0" lower_limit="43.2" upper_limit="137.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" lower_limit="44.5" upper_limit="173.3"/>
                    <measurement group_id="O3" value="57.5" lower_limit="28.6" upper_limit="115.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.6" lower_limit="140.3" upper_limit="644.0"/>
                    <measurement group_id="O3" value="101.2" lower_limit="44.6" upper_limit="229.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.7" lower_limit="120.0" upper_limit="507.3"/>
                    <measurement group_id="O3" value="132.2" lower_limit="64.0" upper_limit="272.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IFN-g, Peptide Pool: M2) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IFN-g, Peptide Pool: M2) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="52.2" upper_limit="135.6"/>
                    <measurement group_id="O2" value="41.2" lower_limit="29.1" upper_limit="58.4"/>
                    <measurement group_id="O3" value="54.9" lower_limit="34.2" upper_limit="88.3"/>
                    <measurement group_id="O4" value="86.6" lower_limit="51.4" upper_limit="145.9"/>
                    <measurement group_id="O5" value="60.5" lower_limit="38.9" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.2" lower_limit="250.9" upper_limit="497.0"/>
                    <measurement group_id="O2" value="247.9" lower_limit="146.6" upper_limit="419.0"/>
                    <measurement group_id="O3" value="418.8" lower_limit="245.4" upper_limit="714.8"/>
                    <measurement group_id="O4" value="352.5" lower_limit="213.9" upper_limit="580.8"/>
                    <measurement group_id="O5" value="49.3" lower_limit="33.0" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.9" lower_limit="197.2" upper_limit="403.0"/>
                    <measurement group_id="O2" value="136.9" lower_limit="76.5" upper_limit="245.1"/>
                    <measurement group_id="O3" value="284.7" lower_limit="157.1" upper_limit="515.7"/>
                    <measurement group_id="O4" value="317.9" lower_limit="217.1" upper_limit="465.4"/>
                    <measurement group_id="O5" value="42.4" lower_limit="31.1" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.9" lower_limit="114.8" upper_limit="300.8"/>
                    <measurement group_id="O2" value="140.5" lower_limit="80.8" upper_limit="244.3"/>
                    <measurement group_id="O3" value="208.8" lower_limit="121.9" upper_limit="357.6"/>
                    <measurement group_id="O4" value="345.5" lower_limit="211.2" upper_limit="565.2"/>
                    <measurement group_id="O5" value="60.4" lower_limit="36.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.2" lower_limit="118.8" upper_limit="364.8"/>
                    <measurement group_id="O2" value="161.1" lower_limit="90.9" upper_limit="285.6"/>
                    <measurement group_id="O3" value="169.6" lower_limit="94.3" upper_limit="305.1"/>
                    <measurement group_id="O4" value="333.4" lower_limit="198.3" upper_limit="560.4"/>
                    <measurement group_id="O5" value="54.6" lower_limit="34.2" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="44.4" upper_limit="169.4"/>
                    <measurement group_id="O3" value="56.3" lower_limit="30.2" upper_limit="104.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.0" lower_limit="126.3" upper_limit="463.7"/>
                    <measurement group_id="O3" value="181.3" lower_limit="75.9" upper_limit="433.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.0" lower_limit="122.5" upper_limit="458.5"/>
                    <measurement group_id="O3" value="216.5" lower_limit="101.0" upper_limit="464.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IFN-g, Peptide Pool: N) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IFN-g, Peptide Pool: N) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.2" lower_limit="114.8" upper_limit="279.7"/>
                    <measurement group_id="O2" value="97.1" lower_limit="62.7" upper_limit="150.3"/>
                    <measurement group_id="O3" value="85.1" lower_limit="53.1" upper_limit="136.3"/>
                    <measurement group_id="O4" value="169.4" lower_limit="107.9" upper_limit="266.2"/>
                    <measurement group_id="O5" value="82.7" lower_limit="51.4" upper_limit="132.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652.1" lower_limit="495.6" upper_limit="857.9"/>
                    <measurement group_id="O2" value="534.9" lower_limit="355.4" upper_limit="805.1"/>
                    <measurement group_id="O3" value="825.9" lower_limit="591.6" upper_limit="1153.0"/>
                    <measurement group_id="O4" value="624.2" lower_limit="421.5" upper_limit="924.5"/>
                    <measurement group_id="O5" value="86.8" lower_limit="58.3" upper_limit="129.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567.7" lower_limit="416.2" upper_limit="774.4"/>
                    <measurement group_id="O2" value="377.2" lower_limit="223.3" upper_limit="637.2"/>
                    <measurement group_id="O3" value="521.3" lower_limit="363.9" upper_limit="746.7"/>
                    <measurement group_id="O4" value="523.4" lower_limit="377.4" upper_limit="726.0"/>
                    <measurement group_id="O5" value="86.5" lower_limit="57.3" upper_limit="130.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.8" lower_limit="353.8" upper_limit="579.6"/>
                    <measurement group_id="O2" value="407.7" lower_limit="259.4" upper_limit="640.9"/>
                    <measurement group_id="O3" value="399.7" lower_limit="292.9" upper_limit="545.6"/>
                    <measurement group_id="O4" value="513.4" lower_limit="359.4" upper_limit="733.4"/>
                    <measurement group_id="O5" value="93.7" lower_limit="58.0" upper_limit="151.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.3" lower_limit="306.8" upper_limit="524.9"/>
                    <measurement group_id="O2" value="401.8" lower_limit="229.4" upper_limit="704.0"/>
                    <measurement group_id="O3" value="386.5" lower_limit="255.7" upper_limit="584.0"/>
                    <measurement group_id="O4" value="544.0" lower_limit="401.7" upper_limit="736.7"/>
                    <measurement group_id="O5" value="78.1" lower_limit="48.9" upper_limit="124.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.3" lower_limit="88.4" upper_limit="305.6"/>
                    <measurement group_id="O3" value="166.2" lower_limit="92.6" upper_limit="298.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475.6" lower_limit="260.9" upper_limit="866.8"/>
                    <measurement group_id="O3" value="385.4" lower_limit="230.1" upper_limit="645.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471.1" lower_limit="325.7" upper_limit="681.4"/>
                    <measurement group_id="O3" value="436.6" lower_limit="268.5" upper_limit="710.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IL-4, Peptide Pool: F) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IL-4, Peptide Pool: F) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="25.0" upper_limit="44.9"/>
                    <measurement group_id="O2" value="29.2" lower_limit="24.1" upper_limit="35.3"/>
                    <measurement group_id="O3" value="44.3" lower_limit="28.5" upper_limit="68.7"/>
                    <measurement group_id="O4" value="49.6" lower_limit="33.8" upper_limit="72.6"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="23.8" upper_limit="32.9"/>
                    <measurement group_id="O2" value="29.0" lower_limit="24.4" upper_limit="34.4"/>
                    <measurement group_id="O3" value="34.1" lower_limit="24.8" upper_limit="46.8"/>
                    <measurement group_id="O4" value="34.8" lower_limit="25.7" upper_limit="47.2"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="32.8" lower_limit="24.9" upper_limit="43.2"/>
                    <measurement group_id="O4" value="35.5" lower_limit="27.9" upper_limit="45.2"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="23.3" upper_limit="30.4"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="30.6" lower_limit="23.9" upper_limit="39.2"/>
                    <measurement group_id="O4" value="29.1" lower_limit="24.0" upper_limit="35.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="23.2" upper_limit="30.7"/>
                    <measurement group_id="O3" value="26.5" lower_limit="23.3" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="23.6" upper_limit="51.1"/>
                    <measurement group_id="O3" value="28.5" lower_limit="21.5" upper_limit="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="22.5" upper_limit="33.4"/>
                    <measurement group_id="O3" value="27.9" lower_limit="23.8" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IL-4, Peptide Pool: G(A)) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IL-4, Peptide Pool: G(A)) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="23.7" upper_limit="43.1"/>
                    <measurement group_id="O2" value="27.7" lower_limit="23.8" upper_limit="32.2"/>
                    <measurement group_id="O3" value="33.7" lower_limit="23.2" upper_limit="49.0"/>
                    <measurement group_id="O4" value="48.2" lower_limit="33.5" upper_limit="69.5"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="23.9" upper_limit="38.7"/>
                    <measurement group_id="O2" value="26.6" lower_limit="23.4" upper_limit="30.2"/>
                    <measurement group_id="O3" value="31.5" lower_limit="24.8" upper_limit="40.0"/>
                    <measurement group_id="O4" value="31.1" lower_limit="25.0" upper_limit="38.7"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="23.9" upper_limit="28.3"/>
                    <measurement group_id="O2" value="26.5" lower_limit="23.5" upper_limit="29.8"/>
                    <measurement group_id="O3" value="26.0" lower_limit="24.0" upper_limit="28.1"/>
                    <measurement group_id="O4" value="33.4" lower_limit="25.1" upper_limit="44.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="22.7" upper_limit="32.9"/>
                    <measurement group_id="O4" value="31.4" lower_limit="24.8" upper_limit="39.8"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="23.0" upper_limit="70.9"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="23.4" upper_limit="46.5"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IL-4, Peptide Pool: G(B)) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IL-4, Peptide Pool: G(B)) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="22.9" upper_limit="39.5"/>
                    <measurement group_id="O2" value="27.4" lower_limit="23.9" upper_limit="31.5"/>
                    <measurement group_id="O3" value="34.2" lower_limit="23.3" upper_limit="50.2"/>
                    <measurement group_id="O4" value="43.4" lower_limit="31.0" upper_limit="60.6"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="21.9" upper_limit="36.1"/>
                    <measurement group_id="O2" value="27.9" lower_limit="23.8" upper_limit="32.7"/>
                    <measurement group_id="O3" value="29.1" lower_limit="22.9" upper_limit="36.8"/>
                    <measurement group_id="O4" value="29.5" lower_limit="24.3" upper_limit="35.7"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="23.5" upper_limit="29.7"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="26.9" lower_limit="23.1" upper_limit="31.3"/>
                    <measurement group_id="O4" value="32.8" lower_limit="25.8" upper_limit="41.7"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="27.2" lower_limit="22.7" upper_limit="32.6"/>
                    <measurement group_id="O4" value="31.3" lower_limit="25.0" upper_limit="39.3"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="23.7" upper_limit="28.9"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="23.2" upper_limit="62.4"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="23.1" upper_limit="38.4"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IL-4, Peptide Pool: M2) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IL-4, Peptide Pool: M2) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="23.8" upper_limit="33.2"/>
                    <measurement group_id="O2" value="25.9" lower_limit="24.1" upper_limit="27.8"/>
                    <measurement group_id="O3" value="39.1" lower_limit="26.3" upper_limit="58.0"/>
                    <measurement group_id="O4" value="28.8" lower_limit="24.3" upper_limit="34.1"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="23.6" upper_limit="33.3"/>
                    <measurement group_id="O2" value="26.7" lower_limit="23.2" upper_limit="30.7"/>
                    <measurement group_id="O3" value="30.8" lower_limit="22.3" upper_limit="42.7"/>
                    <measurement group_id="O4" value="27.0" lower_limit="24.1" upper_limit="30.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="26.0" lower_limit="24.0" upper_limit="28.1"/>
                    <measurement group_id="O3" value="30.6" lower_limit="23.6" upper_limit="39.6"/>
                    <measurement group_id="O4" value="30.0" lower_limit="24.2" upper_limit="37.1"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="24.0" upper_limit="31.2"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="28.1" lower_limit="22.0" upper_limit="36.0"/>
                    <measurement group_id="O4" value="29.5" lower_limit="23.2" upper_limit="37.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="21.2" upper_limit="39.4"/>
                    <measurement group_id="O3" value="28.1" lower_limit="21.8" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="23.2" upper_limit="30.5"/>
                    <measurement group_id="O3" value="26.7" lower_limit="23.2" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT (IL-4, Peptide Pool: N) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT (IL-4, Peptide Pool: N) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Values below the detection limit (DL) are included with a value of '25' (i.e. 1/2 DL)</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="22.9" upper_limit="36.0"/>
                    <measurement group_id="O2" value="32.9" lower_limit="25.9" upper_limit="41.7"/>
                    <measurement group_id="O3" value="41.4" lower_limit="30.8" upper_limit="55.5"/>
                    <measurement group_id="O4" value="35.3" lower_limit="26.1" upper_limit="47.9"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="23.5" upper_limit="29.8"/>
                    <measurement group_id="O2" value="29.1" lower_limit="23.4" upper_limit="36.3"/>
                    <measurement group_id="O3" value="27.9" lower_limit="23.8" upper_limit="32.7"/>
                    <measurement group_id="O4" value="30.2" lower_limit="23.7" upper_limit="38.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="30.1" lower_limit="23.9" upper_limit="37.9"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="28.0" lower_limit="23.7" upper_limit="33.0"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="31.3" lower_limit="24.2" upper_limit="40.5"/>
                    <measurement group_id="O3" value="27.3" lower_limit="24.0" upper_limit="31.1"/>
                    <measurement group_id="O4" value="28.1" lower_limit="23.6" upper_limit="33.5"/>
                    <measurement group_id="O5" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="21.1" upper_limit="39.6"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="22.6" upper_limit="33.1"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: F)</title>
        <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: F)</title>
          <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O2" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="73.9" lower_limit="51.6" upper_limit="89.8"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O2" value="70.0" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O3" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="56.5" lower_limit="34.5" upper_limit="76.8"/>
                    <measurement group_id="O5" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O2" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O3" value="65.0" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O4" value="56.5" lower_limit="34.5" upper_limit="76.8"/>
                    <measurement group_id="O5" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="18.4" upper_limit="67.1"/>
                    <measurement group_id="O2" value="61.1" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="63.6" lower_limit="40.7" upper_limit="82.8"/>
                    <measurement group_id="O5" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="26.6" upper_limit="78.7"/>
                    <measurement group_id="O3" value="21.4" lower_limit="4.7" upper_limit="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="16.3" upper_limit="67.7"/>
                    <measurement group_id="O3" value="14.3" lower_limit="1.8" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(A))</title>
        <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(A))</title>
          <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O3" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O2" value="65.0" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O4" value="69.6" lower_limit="47.1" upper_limit="86.8"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O3" value="70.0" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O4" value="65.2" lower_limit="42.7" upper_limit="83.6"/>
                    <measurement group_id="O5" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="32.9" upper_limit="81.6"/>
                    <measurement group_id="O2" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="63.6" lower_limit="40.7" upper_limit="82.8"/>
                    <measurement group_id="O5" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="50.0" lower_limit="23.0" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="57.1" lower_limit="28.9" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(B))</title>
        <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: G(B))</title>
          <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O2" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O3" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O4" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O5" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="30.8" upper_limit="78.5"/>
                    <measurement group_id="O2" value="55.0" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O3" value="70.0" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O4" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                    <measurement group_id="O5" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="21.8" upper_limit="66.0"/>
                    <measurement group_id="O2" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O3" value="60.0" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O4" value="65.2" lower_limit="42.7" upper_limit="83.6"/>
                    <measurement group_id="O5" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="14.2" upper_limit="61.7"/>
                    <measurement group_id="O2" value="61.1" lower_limit="35.7" upper_limit="82.7"/>
                    <measurement group_id="O3" value="42.1" lower_limit="20.3" upper_limit="66.5"/>
                    <measurement group_id="O4" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O5" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="57.1" lower_limit="28.9" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="42.9" lower_limit="17.7" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: M2)</title>
        <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: M2)</title>
          <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O3" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="87.0" lower_limit="66.4" upper_limit="97.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O2" value="65.0" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="90.0" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O4" value="65.2" lower_limit="42.7" upper_limit="83.6"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O2" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O3" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O4" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O5" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="32.9" upper_limit="81.6"/>
                    <measurement group_id="O2" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O3" value="76.9" lower_limit="46.2" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="76.9" lower_limit="46.2" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: N)</title>
        <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IFN-g, Peptide Pool: N)</title>
          <description>Response rate based on RSV-specific Interferon-gamma (IFN-g) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O2" value="85.7" lower_limit="63.7" upper_limit="97.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O2" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O3" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                    <measurement group_id="O5" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O2" value="84.2" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O3" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="65.2" lower_limit="42.7" upper_limit="83.6"/>
                    <measurement group_id="O5" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" lower_limit="38.3" upper_limit="85.8"/>
                    <measurement group_id="O2" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O3" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O4" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O5" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.3" upper_limit="83.7"/>
                    <measurement group_id="O3" value="78.6" lower_limit="49.2" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.9" upper_limit="95.7"/>
                    <measurement group_id="O3" value="64.3" lower_limit="35.1" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: F)</title>
        <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: F)</title>
          <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool F. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O3" value="30.0" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O4" value="47.8" lower_limit="26.8" upper_limit="69.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O2" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O3" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O4" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O3" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O4" value="34.8" lower_limit="16.4" upper_limit="57.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.1" upper_limit="28.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O3" value="15.8" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O4" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(A))</title>
        <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(A))</title>
          <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(A). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O4" value="43.5" lower_limit="23.2" upper_limit="65.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O3" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O4" value="17.4" lower_limit="5.0" upper_limit="38.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O2" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O4" value="17.4" lower_limit="5.0" upper_limit="38.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="19.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O4" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(B))</title>
        <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: G(B))</title>
          <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool G(B). Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O4" value="39.1" lower_limit="19.7" upper_limit="61.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="0.1" upper_limit="27.3"/>
                    <measurement group_id="O2" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O3" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O4" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O4" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="19.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O4" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: M2)</title>
        <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: M2)</title>
          <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool M2. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="25.0" lower_limit="8.7" upper_limit="49.1"/>
                    <measurement group_id="O4" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="1.4" upper_limit="34.7"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O3" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O4" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O4" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O4" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: N)</title>
        <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
        <time_frame>within 58 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response by ELISPOT (IL-4, Peptide Pool: N)</title>
          <description>Response rate based on RSV-specific Interleukin 4 (IL-4) Enzyme-linked Immuno Spot Technique (ELISPOT) for the Peptide Pool N. Response is defined as the appearance of spot forming units ≥ detection limit (50) for initially negative subjects, or a doubling or more of the spot forming units compared to Baseline for initially positive subjects. Response for main study visits is based on main study Baseline, whereas response for booster study visits is based on booster substudy Baseline. Percentages based on number of subjects with paired data available, i.e. number of subjects with results available for the respective time point and the corresponding Baseline.</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O2" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                    <measurement group_id="O3" value="45.0" lower_limit="23.1" upper_limit="68.5"/>
                    <measurement group_id="O4" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="0.1" upper_limit="27.3"/>
                    <measurement group_id="O2" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O3" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O4" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O2" value="15.8" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="19.5"/>
                    <measurement group_id="O2" value="16.7" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O3" value="10.5" lower_limit="1.3" upper_limit="33.1"/>
                    <measurement group_id="O4" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Memory B Cells (IgG) GMSFU</title>
        <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Immunoglobulin G (IgG)-producing memory B cells. Negative results (i.e. results below 0.01) are included with a value of '0.005'</description>
        <time_frame>within 82 weeks</time_frame>
        <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Memory B Cells (IgG) GMSFU</title>
          <description>Geometric Mean Spot Forming Units (GMSFUs) based on RSV-specific Immunoglobulin G (IgG)-producing memory B cells. Negative results (i.e. results below 0.01) are included with a value of '0.005'</description>
          <population>Immunogenicity Analysis Set i.e. all participants who received at least one vaccination in the main study and were assigned to the subgroup for Peripheral Blood Mononuclear Cells (PBMC) collection. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Main Study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" lower_limit="0.051" upper_limit="0.163"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.046" upper_limit="0.151"/>
                    <measurement group_id="O3" value="0.068" lower_limit="0.034" upper_limit="0.134"/>
                    <measurement group_id="O4" value="0.129" lower_limit="0.073" upper_limit="0.228"/>
                    <measurement group_id="O5" value="0.117" lower_limit="0.061" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.171" lower_limit="0.116" upper_limit="0.251"/>
                    <measurement group_id="O2" value="0.099" lower_limit="0.047" upper_limit="0.210"/>
                    <measurement group_id="O3" value="0.173" lower_limit="0.087" upper_limit="0.344"/>
                    <measurement group_id="O4" value="0.210" lower_limit="0.110" upper_limit="0.399"/>
                    <measurement group_id="O5" value="0.130" lower_limit="0.067" upper_limit="0.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.148" lower_limit="0.093" upper_limit="0.237"/>
                    <measurement group_id="O2" value="0.068" lower_limit="0.034" upper_limit="0.137"/>
                    <measurement group_id="O3" value="0.123" lower_limit="0.051" upper_limit="0.297"/>
                    <measurement group_id="O4" value="0.100" lower_limit="0.053" upper_limit="0.189"/>
                    <measurement group_id="O5" value="0.079" lower_limit="0.042" upper_limit="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (Booster Substudy)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" lower_limit="0.066" upper_limit="0.245"/>
                    <measurement group_id="O3" value="0.138" lower_limit="0.072" upper_limit="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Booster Follow-Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" lower_limit="0.041" upper_limit="0.265"/>
                    <measurement group_id="O3" value="0.231" lower_limit="0.111" upper_limit="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (Booster Follow-Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" lower_limit="0.053" upper_limit="0.202"/>
                    <measurement group_id="O3" value="0.167" lower_limit="0.088" upper_limit="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Number of participants reporting Serious Adverse Events per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
        <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of participants reporting Serious Adverse Events per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between Study Parts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Serious Adverse Events</title>
        <description>Number of participants reporting Serious Adverse Events possibly, probably or definitely related to the trial vaccine per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
        <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Related Serious Adverse Events</title>
          <description>Number of participants reporting Serious Adverse Events possibly, probably or definitely related to the trial vaccine per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between Study Parts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade ≥ 3 Serious Adverse Events</title>
        <description>Number of participants reporting Serious Adverse Events with intensity ≥ Grade 3 per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
        <time_frame>within 108 weeks (Main Study + Booster Substudy)</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade ≥ 3 Serious Adverse Events</title>
          <description>Number of participants reporting Serious Adverse Events with intensity ≥ Grade 3 per period: Between 1st and 2nd vaccination (Vaccination Period 1, Main Study, duration: 4 weeks), between 2nd vaccination and end of active phase of the Main Study (Vaccination Period 2, Main Study, duration: 4 weeks), during the follow-up phase of the Main Study (Follow-Up, Main Study, duration: 22 weeks), after the Main Study and before the booster vaccination (Between Study Parts [retrospectively collected in booster substudy], duration: 26 weeks), between booster vaccination and end of active phase of the Booster Substudy (Booster Vaccination Period, Booster Substudy, duration: 4 weeks), and during the follow-up phase of the Booster Substudy (Follow-Up, Booster Substudy, duration: 48 weeks). Percentages based on number of subjects still in the study at the start of the respective period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between Study Parts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Grade ≥ 3 Adverse Events</title>
        <description>Number of participants reporting Adverse Events possibly, probably or definitely related to the trial vaccine with intensity ≥ Grade 3 per period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Pooled solicited (general only) and unsolicited AEs. Percentages based on number of subjects still in the study at the start of the respective period.</description>
        <time_frame>within 29 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Related Grade ≥ 3 Adverse Events</title>
          <description>Number of participants reporting Adverse Events possibly, probably or definitely related to the trial vaccine with intensity ≥ Grade 3 per period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Pooled solicited (general only) and unsolicited AEs. Percentages based on number of subjects still in the study at the start of the respective period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2, Main Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period, Booster Substudy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local Adverse Events</title>
        <description>Incidence of injection site reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Adverse Events</title>
          <description>Incidence of injection site reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade ≥ 3 Solicited Local Adverse Events</title>
        <description>Incidence of injection site reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade ≥ 3 Solicited Local Adverse Events</title>
          <description>Incidence of injection site reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade ≥ 3 Pain - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Pain - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Pain - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Erythema - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Erythema - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Erythema - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Swelling - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Swelling - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Swelling - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Induration - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Induration - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Induration - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Pruritis - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Pruritis - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Pruritis - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited General Adverse Events</title>
        <description>Incidence of systemic reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited General Adverse Events</title>
          <description>Incidence of systemic reactions (solicited via diary cards) after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade ≥ 3 Solicited General Adverse Events</title>
        <description>Incidence of systemic reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade ≥ 3 Solicited General Adverse Events</title>
          <description>Incidence of systemic reactions (solicited via diary cards) with intensity ≥ Grade 3 after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade ≥ 3 Fever - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Fever - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Fever - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Headache - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Headache - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Headache - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Myalgia - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Myalgia - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Myalgia - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Chills - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Chills - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Chills - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Nausea - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Nausea - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Nausea - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Fatigue - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Fatigue - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Fatigue - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Solicited General Adverse Events</title>
        <description>Incidence of systemic reactions (solicited via diary cards) possibly, probably or definitely related to the trial vaccine after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Related Solicited General Adverse Events</title>
          <description>Incidence of systemic reactions (solicited via diary cards) possibly, probably or definitely related to the trial vaccine after vaccination: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects with a completed diary card for the respective vaccination period.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Related Fever - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Chills - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Chills - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Chills - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Nausea - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Nausea - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Nausea - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue - Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue - Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue - Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Non-serious Adverse Events</title>
        <description>Incidence of unsolicited non-serious adverse events by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
        <time_frame>within 29 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Non-serious Adverse Events</title>
          <description>Incidence of unsolicited non-serious adverse events by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Unsolicited Non-serious Adverse Events</title>
        <description>Incidence of unsolicited non-serious adverse events possibly, probably or definitely related to the trial vaccine by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
        <time_frame>within 29 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Related Unsolicited Non-serious Adverse Events</title>
          <description>Incidence of unsolicited non-serious adverse events possibly, probably or definitely related to the trial vaccine by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade ≥ 3 Unsolicited Non-serious Adverse Events</title>
        <description>Incidence of unsolicited non-serious adverse events with intensity ≥ Grade 3 by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
        <time_frame>within 29 days after vaccination</time_frame>
        <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Single Low Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Two Low Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Single High Dose / Booster</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Two High Doses</title>
            <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Placebo</title>
            <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade ≥ 3 Unsolicited Non-serious Adverse Events</title>
          <description>Incidence of unsolicited non-serious adverse events with intensity ≥ Grade 3 by period: Following the 1st vaccination (Vaccination Period 1, Main Study), following the 2nd vaccination (Vaccination Period 2, Main Study), and following the booster vaccination (Booster Vaccination Period, Booster Substudy). Percentages based on number of subjects having received the respective vaccination.</description>
          <population>Full Analysis Set i.e. all participants who received at least one vaccination in the main study. A subset of participants from groups 1 and 3 entered the booster substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster Vaccination Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>108 weeks for participants of both study parts and 30 weeks for participants of the main study only</time_frame>
      <desc>Serious adverse events were to be reported during the entire study, non-serious adverse events within 4 weeks after each vaccination. Percentages of participants are based on MedDRA Preferred Terms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Single Low Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Two Low Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="E3">
          <title>Group 3 - Single High Dose / Booster</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="E4">
          <title>Group 4 - Two High Doses</title>
          <description>First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)</description>
        </group>
        <group group_id="E5">
          <title>Group 5 - Placebo</title>
          <description>First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

